Navigation Links
Clarient, BioView Initiate Alliance to Finalize Development and Commercialize Non-Invasive Molecular Diagnostic Test for Early Detection of Lung Cancer
Date:12/14/2009

ALISO VIEJO, Calif. and REHOVOT, Israel, Dec. 14 /PRNewswire-FirstCall/ -- Clarient, Inc. (Nasdaq: CLRT), a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, and BioView Ltd. (TASE: BIOV) today jointly announced that they will collaborate on studies to validate the clinical utility of a non-invasive test for the early detection of non-small cell lung cancer. The test, which uses a patient's sputum and was originally developed at the University of Texas M.D. Anderson Cancer Center, is expected to be particularly useful to aid in the diagnosis of early stage lung cancer for smokers and other at-risk populations.

The agreement between the two companies provides Clarient the right to negotiate an exclusive agreement to commercialize the test following its joint development and validation.

Lung cancer is the leading cause of cancer death worldwide, with more than 250,000 newly-diagnosed cases and more than 160,000 deaths annually in the U.S., according to the National Cancer Institute. Non-small cell lung cancer accounts for approximately 85 percent of all lung cancers.

The test uses DNA probes exclusively licensed to BioView by M.D. Anderson Cancer Center and BioView's proprietary Target Fluorescence in situ Hybridization (T-FISH) technology to screen for specific genetic biomarkers that may indicate the presence of cancer cells in sputum. FISH is a well-established diagnostic tool that is the basis of BioView's technology, noted President and Chief Executive Officer Dr. Alan Schwebel.

Initial internal studies of the test have demonstrated its validity, Dr. Schwebel said.

"The sensitivity and specificity obtained to date in our internal studies are better than other non-invasive methods now available for aiding in the early detect
'/>"/>

SOURCE Clarient, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. BioView Reports Interim Results of Early Detection Lung Cancer Diagnostic Test
2. Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock
3. Bayer HealthCare Pharmaceuticals Initiates Phase III Trial with Florbetaben PET Tracer for Imaging of Cerebral beta-Amyloid Plaques, a Pathological Hallmark of Alzheimers Disease
4. Proteon Initiates Second Phase 1/2 Clinical Study of PRT-201 in Hemodialysis Patients
5. New Research Shows Over-use of Asthma Rescue Inhalers Substantially Reduced Through Pharmacist-initiated Physician Intervention
6. Echo Therapeutics Initiates Clinical Study of its New One-Piece Symphony(TM) tCGM Biosensor in Type 1 and Type 2 Diabetic Patients
7. Incept BioSystems Initiates First Human Clinical Trial of its SMART Embryo Culture System for In Vitro Fertilization (IVF)
8. Abbotts XIENCE V(R) Demonstrates Significantly Lower Rates of MACE and Stent Thrombosis Compared to TAXUS(R) Liberte in Investigator-Initiated COMPARE Trial
9. Sangamo BioSciences Announces Plans to Initiate a Second Clinical Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS
10. BioMarin Initiates Phase 2 Clinical Study of PEG-PAL in PKU
11. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... COLUMBUS, Ohio , Aug. 19, 2014 ... Ohio medical device company, announced today that ... FloShield laparoscopic and robotic visualization system in ... approved for sale in Japan ... Corporation is also the exclusive distributor for Karl Storz ...
(Date:8/19/2014)... DUBLIN , Aug. 19, 2014 Research ... "Human Growth Hormone Drugs - Global Strategic Business Report" ... the worldwide markets for Human Growth Hormone Drugs in US$ ... and Others. The report provides separate comprehensive analytics ... Japan , Europe , ...
(Date:8/19/2014)... -- According to Kalorama Information, electronic medical records (EMR) ... in healthcare a reality, and this a factor that ... Recovery and Reinvestment Act, the U.S. government dedicated $20.6 ... will start applying soon for use of paper records.  ... of the EMR industry, EMR 2014: The Market ...
Breaking Medicine Technology:Minimally Invasive Devices and Mitsubishi Medical Japan Forge Exclusive Distribution Agreement 2Global Human Growth Hormone Drugs - Strategic Business Report 2014 2Kalorama: EMR Paves the Way for Big Data 2Kalorama: EMR Paves the Way for Big Data 3
... ANGELES, Jan. 13, 2011 UBM Canon and ... webinar to its webcast series on The Fundamentals of ... on Advanced Assay Technologies and Development Methods ... experts in the industry.   (Logo:   ...
... 13, 2011 CareGiver remote instrument support has expanded ... Medical System, Inc. ("VMSI") is the leading innovator in ... 5 years of success on the SYMPHONY H&E slide ... BenchMark ULTRA, strengthening the integration of the SYMPHONY and ...
Cached Medicine Technology:Advanced Assay Technologies and Development Methods 2CareGiver, Ventana Medical Systems, Inc. Remote Instrument Support, Has Expanded to Include the Ventana BenchMark ULTRA Automated Stainer 2CareGiver, Ventana Medical Systems, Inc. Remote Instrument Support, Has Expanded to Include the Ventana BenchMark ULTRA Automated Stainer 3
(Date:8/20/2014)... August 20, 2014 It’s no secret ... According to the National Institute on Drug Abuse, nearly ... drugs. What’s even more alarming is the fact that ... last decade. , Those locked in a struggle with ... way out. But now, the newly-redesigned AbuseTreatmentCenters.net has released ...
(Date:8/20/2014)... 20, 2014 One Call Alert expands its ... of ResCube, a fully-mobile wearable device that connects customers to ... button, 24 hours a day, 365 days a year. , ... cross country. It operates on the T-Mobile nationwide network like ... in to work. , Like with the other One Call ...
(Date:8/20/2014)... at the Universities of Manchester and Auckland suggest that both ... mechanism. , The findings, published today in the ... or type-1 diabetes and type-2 diabetes are both caused by ... , The results, based on 20 years, work ... both be slowed down and potentially reversed by medicines that ...
(Date:8/20/2014)... Fresh from the cradle of a world-class running city, an ... , Urbini, a new collection of versatile baby gear from ... jogger to its lineup. , The Avi has been in ... the latest racing styles and a set of features to ... a swift, smooth ride on runs, power-walks and causal strolls. ...
(Date:8/20/2014)... 20, 2014 Today, Zane Benefits, the ... open enrollment for 2015. , According to Zane Benefits, ... in November, employees are encouraged to start thinking about ... 2015, the open enrollment period will run from November ... 2015 individuals can purchase a new individual health insurance ...
Breaking Medicine News(10 mins):Health News:Re-Launched AbuseTreatmentCenters.net Offering New List of Substance Abuse Resources 2Health News:One Call Alert Introduces ResCube™, Smallest Mobile Medical Alert System on Market 2Health News:One Call Alert Introduces ResCube™, Smallest Mobile Medical Alert System on Market 3Health News:Scientists show type-1 and type-2 diabetes are caused by same underlying mechanism 2Health News:Urbini Breezes Through Summer with New Jogging Stroller 2
... , , WESTBURY, N.Y., July ... in the Ophthalmic Consultants of Long Island (OCLI) practice will perform ... of sight to those who have lost some or all of ... Cataract USA program, is offering this outpatient surgical procedure to residents ...
... , , , HOUSTON, ... , , If you would like to learn ... Texas Health Institute as they host a morning-long forum on "Building a Federal ... The event will be held at St. Joseph Medical Center, 1401 St. ...
... NxStage Medical, Inc. (Nasdaq: NXTM ), a leading ... financial results for the second quarter ended June 30, 2009 on ... , , NxStage will also host ... 5, 2009 to discuss its second quarter financial results. To listen ...
... , , WALTHAM, Mass., ... and advisory firms focusing on pharmaceutical and healthcare issues, finds that ... million in 2008 to more than $315 million in 2013. The ... Humira and Schering-Plough,s Remicade which recorded sales of $50 million and ...
... , , BANNOCKBURN, Ill., July ... in the United States(1). Yet it,s often not until the untimely passing ... or Tim Russert - that the issue is brought to the forefront ... heightened focus on heart health, a recent survey(2) uncovered that only 14 ...
... on intelligence tests at age 5 , MONDAY, July ... of a common airborne pollutant compound seems to threaten ... , The finding is based on the experience of ... City area. Specifically, it indicates that high prenatal exposure ...
Cached Medicine News:Health News:Ophthalmic Consultants of Long Island (OCLI), the Largest and One of the Most Prestigious Multi-Specialty Ophthalmology Practices on Long Island, Participates in Mission Cataract USA 2Health News:Ophthalmic Consultants of Long Island (OCLI), the Largest and One of the Most Prestigious Multi-Specialty Ophthalmology Practices on Long Island, Participates in Mission Cataract USA 3Health News:Building a Federal Health Board - Impact on Texas 2Health News:NxStage to Report Second Quarter 2009 Financial Results 2Health News:Brazil's Rheumatoid Arthritis Drug Market Will Grow $115 Million by 2013 2Health News:Need for At-Home Blood Pressure Monitoring Underscored by High-Profile Cardiac Deaths 2Health News:Need for At-Home Blood Pressure Monitoring Underscored by High-Profile Cardiac Deaths 3Health News:Exposure to Common Pollutant in Womb Might Lower IQ 2Health News:Exposure to Common Pollutant in Womb Might Lower IQ 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: